Effect of Imipenem, Fosfomycin, Colistin, and Gentamicin Combination Against Carbapenem-resistant and Biofilm-forming Isolated from Burn Patients

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2021 Sep 27

PMID 34567162

Citations 14

Authors

Mohammad Yousef Memar

Khosro Adibkia

Safar Farajnia

Hossein Samadi Kafil

Younes Khalili

Robab Azargun

Reza Ghotaslou

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to investigate antibacterial and antibiofilm effect of colistin, imipenem, gentamicin, and fosfomycin alone and the various combinations against carbapenem-resistant (. Eight carbapenem-resistant and biofilm-forming isolates from burn patients were collected. The mechanisms of resistance to carbapenem were determined by the phenotypic, PCR, and Real-Time PCR assays. The minimum inhibitory concentration (MIC) of antimicrobial agents was determined by the broth micro dilution. To detect any inhibitory effect of antibiotics against the biofilm, the biofilm inhibitory concentration was determined. To detect synergetic effects of the combinations of antibiotics, the checkerboard assay and the fractional inhibitory concentration (FIC) were used. The highest synergic effect was observed in colistin/fosfomycin and gentamicin/fosfomycin (5 of 8 isolates), and the lowest synergic effect was found in gentamicin/imipenem and colistin/gentamicin (1 of 8 isolates). Colistin/fosfomycin, imipenem/fosfomycin, colistin/imipenem, gentamicin/fosfomycin, and gentamicin/imipenem were shown synergic effect for 3, 2, 2, 2 and 1 isolates, respectively. The combination of antibiotics had different effects on biofilm and planktonic forms of . Therefore, a separate determination of inhibitory effects of the antibiotic in the combination is necessary. Fosfomycin/colistin and fosfomycin/gentamicin were more effective against planktonic form and fosfomycin/colistin against biofilm forms.

Citing Articles

Virulence genes and antibiotic susceptibility patterns of isolated from nosocomial urinary tract infections in the northwest of Iran during 2022-2023: A cross-sectional study.

Memar M, Vosughi M, Rahbar Saadat Y, Ardalan M, Yekani M, Niknafs B Health Sci Rep. 2024; 7(11):e70149.

PMID: 39479286 PMC: 11522605. DOI: 10.1002/hsr2.70149.

Critical resistance to carbapenem and aminoglycosides in Pseudomonas aeruginosa: spread of bla/16S methylase armA harboring isolates with intrinsic resistance mechanisms in Kerman, Iran.

Soltani B, Ahmadrajabi R, Kalantar-Neyestanaki D BMC Infect Dis. 2024; 24(1):1188.

PMID: 39434025 PMC: 11494745. DOI: 10.1186/s12879-024-10085-w.

Activity of polymyxin B combined with cefepime-avibactam against the biofilms of polymyxin B-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae in in vitro and in vivo models.

Tian M, Yan B, Jiang R, Liu C, Li Y, Xu B BMC Microbiol. 2024; 24(1):409.

PMID: 39407114 PMC: 11481319. DOI: 10.1186/s12866-024-03571-3.

Enhancing antimicrobial efficacy against Pseudomonas aeruginosa biofilm through carbon dot-mediated photodynamic inactivation.

Shiralizadeh S, Farmany A, Shokoohizadeh L, Pourhajibagher M, Alikhani M, Bahador A AMB Express. 2024; 14(1):108.

PMID: 39342036 PMC: 11438754. DOI: 10.1186/s13568-024-01766-5.

Identification of gene in resistant strains isolated from cows and humans in Basra province, Iraq.

Jasim A, Mohammed A, Abbas W, Ibraheim H, Gharban H Vet World. 2024; 17(7):1629-1636.

PMID: 39185049 PMC: 11344103. DOI: 10.14202/vetworld.2024.1629-1636.

References

Dundar D, Otkun M . In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains. Yonsei Med J. 2010; 51(1):111-6. PMC: 2799966. DOI: 10.3349/ymj.2010.51.1.111. View

Tredget E, Shankowsky H, Rennie R, Burrell R, Logsetty S . Pseudomonas infections in the thermally injured patient. Burns. 2003; 30(1):3-26. DOI: 10.1016/j.burns.2003.08.007. View

Okazaki M, Suzuki K, Asano N, Araki K, Shukuya N, Egami T . Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother. 2002; 8(1):37-42. DOI: 10.1007/s101560200004. View

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

Ghorbani H, Memar M, Sefidan F, Yekani M, Ghotaslou R . In vitro synergy of antibiotic combinations against planktonic and biofilm Pseudomonas aeruginosa. GMS Hyg Infect Control. 2017; 12:Doc17. PMC: 5647455. DOI: 10.3205/dgkh000302. View

Quale J, Bratu S, Gupta J, Landman D . Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2006; 50(5):1633-41. PMC: 1472219. DOI: 10.1128/AAC.50.5.1633-1641.2006. View

Roussos N, Karageorgopoulos D, Samonis G, Falagas M . Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009; 34(6):506-15. DOI: 10.1016/j.ijantimicag.2009.08.013. View

Di X, Wang R, Liu B, Zhang X, Ni W, Wang J . In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa. J Antibiot (Tokyo). 2015; 68(9):551-5. DOI: 10.1038/ja.2015.27. View

Hayashi I, Sakurai M, Karato A, Ichiki M, Sekine I, Ishikawa T . [Laboratory and clinical studies on combined effects of fosfomycin plus sulbactam/cefoperazone for mixed infections of MRSA and Pseudomonas aeruginosa]. Jpn J Antibiot. 1994; 47(8):991-1005. View

10.

Tessier F, Quentin C . In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1997; 16(2):159-62. DOI: 10.1007/BF01709477. View

11.

Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A . Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013; 57(3):1421-7. PMC: 3591882. DOI: 10.1128/AAC.01718-12. View

12.

Denton M, Kerr K, Mooney L, Keer V, Rajgopal A, Brownlee K . Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol. 2002; 34(4):257-61. DOI: 10.1002/ppul.10166. View

13.

Wu H, Moser C, Wang H, Hoiby N, Song Z . Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2014; 7(1):1-7. PMC: 4817533. DOI: 10.1038/ijos.2014.65. View

14.

Britt N, Ritchie D, Kollef M, Burnham C, Durkin M, Hampton N . Importance of Site of Infection and Antibiotic Selection in the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Sepsis. Antimicrob Agents Chemother. 2018; 62(4). PMC: 5913923. DOI: 10.1128/AAC.02400-17. View

15.

Bergen P, Forrest A, Bulitta J, Tsuji B, Sidjabat H, Paterson D . Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother. 2011; 55(11):5134-42. PMC: 3195049. DOI: 10.1128/AAC.05028-11. View

16.

Vestergaard M, Paulander W, Marvig R, Clasen J, Jochumsen N, Molin S . Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents. 2015; 47(1):48-55. DOI: 10.1016/j.ijantimicag.2015.09.014. View

17.

Joo E, Kang C, Ha Y, Kang S, Park S, Chung D . Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist. 2011; 17(2):305-12. DOI: 10.1089/mdr.2010.0170. View

18.

Petrosillo N, Ioannidou E, Falagas M . Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect. 2008; 14(9):816-27. DOI: 10.1111/j.1469-0691.2008.02061.x. View

19.

Nakamura T, Hashimoto Y, Kokuryo T, Inui K . Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharm Res. 1998; 15(5):734-8. DOI: 10.1023/a:1011971019868. View

20.

Nakamura I, Yamaguchi T, Tsukimori A, Sato A, Fukushima S, Matsumoto T . New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014; 34(1):83-87. DOI: 10.1007/s10096-014-2192-x. View